# RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS

> **NCT00126672** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 36 (actual)

## Conditions studied

- Nonmalignant Neoplasm
- Tuberous Sclerosis
- Lymphangioleimyomatosis
- Kidney Angiomyolipoma

## Interventions

- **DRUG:** Rapamycin

## Key facts

- **NCT ID:** NCT00126672
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12-20
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-04-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126672, "RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT00126672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*